Edition:
United Kingdom

Repligen Corp (RGEN.OQ)

RGEN.OQ on NASDAQ Stock Exchange Global Select Market

57.30USD
14 Dec 2018
Change (% chg)

$-1.78 (-3.01%)
Prev Close
$59.08
Open
$58.75
Day's High
$59.84
Day's Low
$57.18
Volume
161,999
Avg. Vol
155,637
52-wk High
$70.47
52-wk Low
$29.58

Latest Key Developments (Source: Significant Developments)

Sartorius Stedim Biotech And Repligen Corporation Partner On Next-Gen Perfusion-Enabled Bioreactors
Tuesday, 4 Sep 2018 

Sept 4 (Reuters) - SARTORIUS STEDIM BIOTECH SA ::SARTORIUS STEDIM BIOTECH SA - SARTORIUS STEDIM BIOTECH AND REPLIGEN CORPORATION PARTNER TO INTRODUCE NEXT-GENERATION PERFUSION-ENABLED BIOREACTORS.  Full Article

Repligen Announces Agreement With Navigo Proteins For The Exclusive Co-Development Of Next Generation Affinity Ligands
Wednesday, 27 Jun 2018 

June 27 (Reuters) - Repligen Corp ::REPLIGEN ANNOUNCES AGREEMENT WITH NAVIGO PROTEINS FOR THE EXCLUSIVE CO-DEVELOPMENT OF NEXT GENERATION AFFINITY LIGANDS.REPLIGEN-CO & NAVIGO WILL CO-DEVELOP PORTFOLIO OF NEXT GENERATION LIGANDS, UTILIZING NAVIGO'S PROPRIETARY PRECISION CAPTURING TECHNOLOGY PLATFORM.REPLIGEN - UNDER AGREEMENT, CO RECEIVES INTELLECTUAL PROPERTY RIGHTS AND EXCLUSIVITY ON ALL AFFINITY LIGANDS DEVELOPED WITH NAVIGO.REPLIGEN CORP - UNDER AGREEMENT, NAVIGO RECEIVES A SERIES OF MILESTONE AND ROYALTY PAYMENTS.REPLIGEN CORP - FORMAL AGREEMENT EXPANDS ON A TWO-YEAR RELATIONSHIP BETWEEN REPLIGEN AND NAVIGO.  Full Article

Repligen reports Q3 adjusted non-GAAP earnings per share $0.15
Thursday, 9 Nov 2017 

Nov 9 (Reuters) - Repligen Corp :Repligen reports third quarter 2017 financial results.Q3 adjusted non-GAAP earnings per share $0.15.Q3 GAAP earnings per share $0.11.Q3 revenue $36.6 million versus I/B/E/S view $35.3 million.Q3 earnings per share view $0.11 -- Thomson Reuters I/B/E/S.Sees fy 2017 adjusted earnings per share $0.60 to $0.63.Sees fy 2017 GAAP earnings per share $0.38 to $0.41.Repligen Corp sees fy 2017 GAAP gross margin in range of 52.5 pct-53.5 pct​.Repligen Corp - sees fy 2017 revenue in range of $139-$142 million, narrowing previous guidance of $138-$144 million​.Fy2017 revenue view $140.6 million -- Thomson Reuters I/B/E/S.Fy2017 earnings per share view $0.59 -- Thomson Reuters I/B/E/S.  Full Article

Repligen extends long term supply agreement with Purolite for Protein A ligands
Tuesday, 7 Nov 2017 

Nov 7 (Reuters) - Repligen Corp :Repligen extends long term supply agreement with Purolite for Protein A ligands.Repligen Corp - ‍Pursuant to agreement, co will supply Protein A ligands to purolite through November 2022, with an option for renewal through 2025​.Repligen - ‍Pursuant to agreement, Repligen will supply Protein A ligands to Purolite through November 2022, with an option for renewal through 2025​.  Full Article

Repligen prices public offering of shares of common stock
Wednesday, 28 Jun 2017 

June 27 (Reuters) - Repligen Corp ::Repligen Corporation prices public offering of shares of common stock.Says public offering of 2.81 million common shares priced at $42.75 per share.  Full Article